Although further mechanistic studies such as stimulating fibroblasts with TARC are needed to investigate whether and to what extent TARC is involved in SSc-ILD, serum TARC levels do not predict the severity or disease activity of SSc-ILD, which suggests that TARC does not directly cause fibrosis. Here, CCL17 is linked to systemic sclerosis.